EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimal hyperglycemia thresholds in patients undergoing chemotherapy: a cross sectional study of oncologists’ practices

Teresa M Salgado, Poorva B Birari, Mona Alshahawey, Erin Hickey Zacholski, Emily Mackler, Tonya M Buffington, Kerri T Musselman, William J Irvin, Jennifer M Perkins, Trang N Le, Dave L Dixon, Karen B Farris und 2 weitere

Supportive Care in Cancer · 2024

DOI: 10.1007/s00520-024-08756-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Teresa M Salgado und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy & Outcomes Science, School of Pharmacy and Massey Cancer Center, Virginia Commonwealth University, 410 N. 12Th Street P…. Hauptthemen laut MEDLINE: Hyperglycemia, Blood Glucose, Glycated Hemoglobin, Practice Patterns, Physicians'. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Association of Colleges of Pharmacy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Neither the United States nor the European oncology guidelines include details for appropriate management of hyperglycemia in cancer patients. The aim was to identify fasting and random blood glucose thresholds, and hemoglobin A1c (HbA1c) targets used by oncologists in clinical practice when managing hyperglycemia in patients with cancer undergoing chemotherapy.

Methods

This national, cross sectional study utilized a questionnaire to collect oncologists’ perceptions about optimal blood glucose thresholds and HbA1c targets in patients with cancer undergoing chemotherapy. Descriptive statistics were calculated to summarize glucose thresholds, HbA1c targets, and sample characteristics. Responses to an open-ended question about oncologists’ approach to hyperglycemia management were analyzed via thematic analysis using an inductive approach.

Results

Respondents ( n = 229) were on average 52.1 years of age, 67.7% men, and 91.3% White. For patients without diabetes but experiencing hyperglycemia, oncologists targeted lower and upper fasting blood glucose levels between 75-121 mg/dL and 105-135 mg/dL, respectively. For patients with diabetes, the targets for lower and upper fasting blood glucose levels ranged between 100-130 mg/dL and 128-150 mg/dL, respectively. Fasting blood glucose (95.6%) and HbA1c (78.6%) were the most commonly used clinical indicators to consider chemotherapy dose reduction, delay, or discontinuation due to hyperglycemia in patients receiving chemotherapy with curative intent. Among those receiving palliative intent chemotherapy, the preferred clinical parameters were random blood glucose (90.0%), patient-reported blood glucose readings (70.7%), continuous glucose monitoring readings (65.1%), and patient-reported symptoms of hyperglycemia (65.1%). Three main themes emerged about oncologists’ approach to hyperglycemia management: 1) identification of high-risk patients; 2) need for early identification, screening, and diagnosis of hyperglycemia; and 3) multiple hyperglycemia management strategies.

Conclusion

Oncologists reported a wide variation of target blood glucose ranges considered appropriate in patients undergoing chemotherapy. Lack of clear guidance for hyperglycemia management during chemotherapy in the United States may be contributing to a lack of consistency in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperglycemiaBlood GlucoseGlycated HemoglobinPractice Patterns, Physicians'NeoplasmsOncologistsAntineoplastic AgentsHumansCross-Sectional StudiesMaleFemaleMiddle AgedSurveys and QuestionnairesAdultAgedUnited States

Stichwörter der Autor:innen

HyperglycemiaOncologists [MeSH]Practice Patterns, Physicians’ [MeSH]Surveys and Questionnaires [MeSH]

Substanzen

Blood GlucoseGlycated HemoglobinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacotherapy & Outcomes Science, School of Pharmacy and Massey Cancer Center, Virginia Commonwealth University, 410 N. 12Th Street PO Box 98053, Richmond, VA, 23298, USA. tmsalgado@vcu.edu.
  • Department of Pharmacotherapy & Outcomes Science, School of Pharmacy, Virginia Commonwealth University, 410 N. 12Th Street PO Box 98053, Richmond, VA, 23298, USA.
  • Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Organization of African Unity St, El-Qobba Bridge, El Weili, Cairo Governorate, 4393005, Egypt.
  • Michigan Oncology Quality Consortium (MOQC) and Michigan Institute for Care Management and Transformation (MICMT), 4251 Plymouth Road Arbor Lakes, Building 3, Floor 3, Ann Arbor, MI, 48105, USA.
  • Bon Secours Mercy Health, 611 Watkins Centre Parkway, Suite 250, Midlothian, VA, 23114, USA.
  • Emcara Health and PopHealthCare, 113 Seaboard Lane, Suite B200, Franklin, TN, 37067, USA.

Förderung

  • American Association of Colleges of Pharmacy

Zitieren

APA

Salgado, T. M., Birari, P. B., Alshahawey, M., Hickey Zacholski, E., Mackler, E., Buffington, T. M., Musselman, K. T., Irvin, W. J., Perkins, J. M., Le, T. N., Dixon, D. L., Farris, K. B., Sheppard, V. B., & Jones, R. M. (2024). Optimal hyperglycemia thresholds in patients undergoing chemotherapy: a cross sectional study of oncologists’ practices. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-08756-0

Vancouver

Salgado TM, Birari PB, Alshahawey M, Hickey Zacholski E, Mackler E, Buffington TM, et al. Optimal hyperglycemia thresholds in patients undergoing chemotherapy: a cross sectional study of oncologists’ practices. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-08756-0

BibTeX
@article{Salgado2024,
  author = {Salgado, Teresa M and Birari, Poorva B and Alshahawey, Mona and Hickey Zacholski, Erin and Mackler, Emily and Buffington, Tonya M and Musselman, Kerri T and Irvin, William J and Perkins, Jennifer M and Le, Trang N and Dixon, Dave L and Farris, Karen B and Sheppard, Vanessa B and Jones, Resa M},
  title = {Optimal hyperglycemia thresholds in patients undergoing chemotherapy: a cross sectional study of oncologists’ practices},
  journal = {Supportive Care in Cancer},
  year = {2024},
  doi = {10.1007/s00520-024-08756-0}
}
Kostenlos starten →